These studies were on 89Zr-bevacizumab, an anti-endothelial growth factor (VEGF)-A mAb, in patients with breast cancer [9] and 89Zr-labeled anti-membrane-bound surface glycoprotein mesothelin (MSLN) mAb in patients with pancreatic and ovarian cancer [10]. This evidence concerns the gene MSLN and breast cancer.